Literature DB >> 365009

Preoperative prophylactic cephalothin fails to control septic complications of colorectal operations: results of controlled clinical trial. A Veterans Administration cooperative study.

R E Condon, J G Bartlett, R L Nichols, W J Schulte, S L Gorbach, S Ochi.   

Abstract

Data obtained from a survey of the membership of the Society for Surgery of the Alimentary Tract and the American Society of Colon and Rectal Surgeons indicated that concomitant administration of oral neomycin-erythromycin base and systemic cephalothin, together with mechanical colon cleansing, was the most popular method of colon preparation. We designed a prospective double blind clinical trial to compare administration of intravenous cephalothin, oral neomycin-erythromycin base, and the combination of both the intravenous and oral antibiotics. Intake of patients to the intravenous cephalothin group was stopped because the data indicated that this method of prophylaxis resulted in significantly higher numbers of septic complications. The incidence of wound infection was 30 per cent and the overall incidence of septic complications was 39 per cent in patients receiving only intravenous cephalothin combined with mechanical colon cleansing. The incidence of wound infection and the overall incidence of septic complications was only 6 per cent in the comparison group, and the differences are highly significant.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 365009     DOI: 10.1016/0002-9610(79)90013-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  19 in total

1.  Pelvic drainage should be a routine for TME with or without radiation.

Authors:  Tsuyoshi Konishi; Toshiaki Watanabe; Hirokazu Nagawa
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

2.  Randomized clinical trial comparing intravenous antimicrobial prophylaxis alone with oral and intravenous antimicrobial prophylaxis for the prevention of a surgical site infection in colorectal cancer surgery.

Authors:  Minako Kobayashi; Yasuhiko Mohri; Hitoshi Tonouchi; Chikao Miki; Keiji Nakai; Masato Kusunoki
Journal:  Surg Today       Date:  2007-04-30       Impact factor: 2.549

3.  Antimicrobial prophylaxis and colon preparation for colorectal surgery: Results of a questionnaire survey of 721 certified institutions in Japan.

Authors:  Minako Kobayashi; Yoshio Takesue; Yuko Kitagawa; Masato Kusunoki; Yoshinobu Sumiyama
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

4.  Cefotaxime i.v. versus oral neomycin-erythromycin for prophylaxis of infections after colorectal operations.

Authors:  D Raahave; P Hesselfeldt; T B Pedersen
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

5.  Surgical wound infections. A 5-year prospective study of 20,193 wounds at the Minneapolis VA Medical Center.

Authors:  M Olson; M O'Connor; M L Schwartz
Journal:  Ann Surg       Date:  1984-03       Impact factor: 12.969

6.  Prevention and treatment of infection in colorectal surgery.

Authors:  M R Keighley
Journal:  World J Surg       Date:  1982-05       Impact factor: 3.352

7.  Colectomy, mucosal proctectomy, and ileal pouch-anal anastomosis. A prospective trial of optimal antibiotic management.

Authors:  J M Becker; D P Alexander
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

8.  Determinants of wound infection after colon surgery.

Authors:  E Simchen; M Shapiro; T G Sacks; J Michel; A Durst; Z Eyal
Journal:  Ann Surg       Date:  1984-03       Impact factor: 12.969

9.  Pharmacokinetics and tissue penetration of a single dose of ornidazole (1,000 milligrams intravenously) for antibiotic prophylaxis in colorectal surgery.

Authors:  C Martin; B Bruguerolle; M N Mallet; M Condomines; B Sastre; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

10.  Penetration of antibiotics into the surgical wound in a canine model.

Authors:  E Rosin; S Ebert; T S Uphoff; M H Evans; N J Schultz-Darken
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.